Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Summary

Halozyme announced a global collaboration and license agreement with Incyte (INCY) to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE technology. The deal represents a strategic partnership to advance subcutaneous delivery of Incyte's drug candidate.